news

Gene therapy for DMD safely preserves muscle function

Gene therapy for the treatment of Duchenne muscular dystrophy has safely stopped the muscle deterioration associated with the disease.

FCMD-gene-therapy

A gene therapy developed to treat Duchenne muscular dystrophy (DMD) has safely stopped the severe muscle deterioration associated with the disease in both small and large animal models.

This is according to a first-of-its-kind study from Penn Medicine, US researchers which could lead to a safe and effective gene therapy that uses a ‘substitute’ protein without triggering immune responses known to hinder other therapeutic approaches.

With their modified gene therapy approach, the research team engineered adeno-associated virus (AAV) vectors to deliver a ‘substitute’ protein for dystrophin in animal DMD models to keep the muscles intact. The synthetic substitute, based on a protein called utrophin, proved to be an effective and safe alternative, as it protected muscle in mice and dogs with naturally occurring DMD-like mutations, including a large deletion that closely mirrors the large dystrophin deletions found in humans.

 

Reserve your FREE place

 


Are you looking to optimise antibody leads in your drug discovery? Register for this webinar to find out how!

30 July 2025 | 10:00 AM BST | FREE Webinar

Join this webinar to hear from Dr. Lei Guo as she shares how early insights into liability, PK, stability, and manufacturability can help you optimise antibody leads in early drug discovery – and mitigate downstream risks later in development.

What You’ll Learn:

  • How to assess key developability risks early
  • How in silico modelling and in vitro testing can be combined to predict CMC risks earlier in discovery stage
  • How micro-developability strategies are tailored for complex or novel formats

Don’t miss your chance to learn from real-world leaders

Register Now – It’s Free!

 

“For the first time, we’ve shown how a carefully constructed version of a dystrophin-related protein can safely prevent the breakdown of muscle and maintain its function over time in the most informative animal models. This discovery has important implications for gene therapy and how we work towards safe and effective treatments for muscular dystrophy,” said senior author Hansell H Stedman, MD, an associate professor of Surgery. 

With these results, we have a strong rationale to move this forward into human clinical trials.”

This is the first large animal study to show utrophin’s effectiveness as well as its non-immunogenic response. Taken together, the researchers said, these findings may refocus the field toward the use of a functionally optimised, safe utrophin-based gene therapy approach as the pathway to a potential cure for DMD.

To create Penn’s synthetic version, a team of researchers first turned to evolutionary biology to better understand dystrophin’s origin and how it was assembled, looking back and reconstructing genetic events throughout history. Ongoing studies would reveal more about the protein’s makeup, the strength of its rod structure and its deletions, among other important characteristics, to inform future development.

“We have gained a lot of insight from that approach,” Stedman said. “One of the things that we hope to do during clinical development is to leverage that insight to make ever better therapies, the strongest possible versions of ‘nanotrophin’.”

The study was published in Nature Medicine.

Leave a Reply

Your email address will not be published. Required fields are marked *